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Abstract
BACKGROUND: Ovarian cancer overexpresses ET-1, and in vitro studies have shown that ET-1 confers resistance to
anthracycline-containing chemotherapy. Atrasentan has been developed as an oral selective endothelin-A receptor an-
tagonist. Theobjective of the studywas to investigate the feasibility and toxicity of adding increasingdosesof atrasentan
(to amaximumof 10mg/d) and liposomal doxorubicin in patientswith progressive ovarian cancer, refractory for platinum
and paclitaxel.METHODS: Patients with platinum-resistant ovarian cancer were treated with pegylated liposomal doxo-
rubicin (PLD) 50mg/m2 on day 1 (and repeated every 4 weeks) in combination with escalating doses of atrasentan once
daily. The starting dose was 2.5 mg and escalated in cohorts of three patients from 5 to 10 mg. RESULTS: Twenty-six
patients (mean age = 60 years, range = 42-74 years) were treated at the three dose levels. Atrasentan could be safely
administered in combination at a dose of 10mg. All patients were evaluable for toxicity, and 19 patients, included in the
phase 2 period, were evaluable for response. Adverse events included nausea, vomiting, mucositis, skin toxicity, and
rhinitis. Clinical cardiac toxicity, intensivelymonitored,was not observed, although twopatients had a decrease in cardiac
ejection fraction. Three objective responses were observed and another six patients had stable disease with a median
time to progression of 14weeks and an overall survival of 13.1months.CONCLUSIONS: The addition of atrasentan to
standard dose PLD in platinum-resistant ovarian cancer is feasible with some suggestion of prolonged survival.
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Introduction
Ovarian cancer is the fifth most common cancer among women and
also the leading cause of gynecologic cancer–related deaths [1]. De-
spite advances in cytoreductive surgery and chemotherapy, only slight
improvements in long-term survival have been observed. The current
standard first-line chemotherapy consists of a platinum compound
combined with paclitaxel [2]. With interventions, most patients attain
complete clinical remission. Most patients, however, eventually relapse
and die of progressive drug-resistant disease [3]. When platinum- and
taxane-resistant disease is reached, agents that lack cross-resistance
with platinum compounds are required. On the basis of survival and
toxicity advantages and a once-a-month administration schedule,
pegylated liposomal doxorubicin (PLD) is the first-choice nonplatinum
agent for relapsed disease [4,5]. However, the effect on survival is mod-
est, and the development of new treatment modalities to obtain more
prolonged survival is therefore highly needed.
The endothelin family of peptides (ET) is identified as contributing
to the pathophysiology of cancer. Its role in the modulation of mito-
genesis, apoptosis, angiogenesis, tumor invasion, and development of
metastases makes it an attractive target for therapy [6]. Elevated levels of
ET-1 have been demonstrated in a variety of human tumors, including
ovarian cancer and several other endocrine-responsive malignancies
including prostate and cervical cancer [7–10].
ET-1, the most important isoform in cancer among the three ETs, is
produced by many epithelial cells and binds to its cognate G protein–
coupled receptor. There are two receptor subtypes; ETA and ETB, the
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ETAR being the one that binds to ET-1 with the highest affinity. The
increased expression of both ET-1 and ETAR in human tumors sug-
gests an autocrine or paracrine mechanism of tumoral growth promo-
tion or maintenance [7].
The ETAR is therefore an attractive potential target for anticancer
therapy. In this light, ABT-627 (atrasentan), an orally bioavailable
selective ETAR antagonist, was developed to interrupt ETAR signaling.
Numerous preclinical studies have confirmed the importance of the
ET/ETAR pathway and its validity as an anticancer target. Successful
data of in vitro and in vivo inhibition of proliferation, angiogenesis, and
invasion with single agent therapy were further improved through
combination with cytotoxic agents, in particular the taxanes [8,9].
In phase 1 dose-escalation studies, the pharmacokinetics of atrasentan
were linear, dose-proportional, and time independent over a 2.5- to
95-mg daily dose range, with steady-state plasma concentrations reach-
ing biologically relevant levels (mean unbound Cmin for the 10-mg
daily dose was eight-fold greater than that of ETARKi) [8]. Atrasentan
was well tolerated with a safety profile reflective of its vasodilator prop-
erties through ETAR antagonism. The most common adverse effects
were attributable to the vasoactive nature, including rhinitis, headache,
peripheral edema, and anemia (caused by hemodilution) [9,11–13].
In a randomized, placebo-controlled phase 2 study with atrasentan
in prostate cancer prolongation of time to progression (TTP) was seen
[14]; however, in the following phase 3 study, atrasentan did not delay
disease progression in men with metastatic prostate cancer despite
evidence of biologic effects on markers of disease burden [13]. A phase
1/2 study of atrasentan plus paclitaxel-carboplatin in advanced non–
small cell lung carcinoma was safe and well tolerated, with no apparent
paclitaxel-atrasentan pharmacokinetic interaction. Efficacy and survival
were comparable with studies of chemotherapy alone [15]. A phase 2
study with another endothelin A antagonist in melanoma showed ben-
efit in disease stabilization when given as monotherapy [16].
We performed a phase 1/2 trial combining PLD and atrasentan.
The primary objectives of the phase 1 period was to establish the safety
profile and determine a safe dose for phase 2 testing of atrasentan com-
bined with PLD when administered simultaneously. The primary ob-
jective of the phase 2 period of this trial in patients with refractory
ovarian carcinoma was to determine the response rate of the combina-
tion according to a conventional study design. Secondary end points
were progression-free survival (PFS) and overall survival (OS).
Patients and Methods
All patients were assigned in the University Medical Center Utrecht,
The Netherlands. Before performance of study-specific procedures,
patients gave signed informed consent. The clinical protocol, any pro-
tocol amendments, the informed consent, and other necessary docu-
ments were reviewed and approved by the institutional review board/
independent ethics committee before initiation of the study. Blinding
of investigational products or study data was not performed.
Assessments
Adverse events, laboratory profiles, electrocardiograms, left ventric-
ular ejection fraction (LVEF) bymultigated acquisition (MUGA) scan,
physical examinations, and vital signs were assessed throughout the
study. If a single patient in the phase 1 period within a cohort experi-
enced a dose-limiting toxicity (DLT), escalation of any subsequent co-
horts did not continue until an additional three patients had been
enrolled and dosed at the same dose level, and these three new patients
did not exhibit a DLT. Toxicities (both acute and intermediate) were
measured each visit using the CTC, version 2.0 (National Cancer
Institute, Bethesda, MD). If any of the additional three patients exhib-
ited any grade 3 or 4 toxicity, then this dose was considered the maxi-
mum tolerable dose.
Efficacy variables used were response rate using RECIST criteria,
OS as measured from study registration, PFS as measured from study
registration until progressive disease or death, and response duration
as measured from the first moment a response, either complete or
partial response, was noted till progression. Duration of stable disease
was measured from start of study registration. Tumor measurements
were performed before start of treatment and after every two cycles
thereafter. Patients were followed until progressive disease.
Eligibility Criteria
All patients were required to have histologically confirmed epithe-
lial ovarian cancer that was resistant to platinum (progression during
platinum therapy or in the following 6 months). Further entry criteria
were as follows age older than 18 years;WorldHealth Organization per-
formance status 0 to 2; measurable disease according to the RECIST
criteria; adequate renal, hepatic, and bone marrow functions; and
adequate cardiac function to tolerate treatment and controllable hyper-
tension. The life expectancy had to be at least 3 months.
Exclusion criteria were as follows: another previous or present ma-
lignancy other than ovarian cancer, except cured stage I cervical cancer
and nonmelanoma skin cancer; radiation therapy less than 4weeks before
start of study treatment; previous chemotherapy less than 3 weeks before
start of study treatment; presence of disease with immune etiology that
might exacerbate because of study treatment and/or active infection;
known positive testing for human immunodeficiency virus; clinical neu-
rologic examination suggesting cerebral metastasis; known history of car-
diovascular disability status of New York Heart Association class 2 or
higher; and allergy for medication to be used. The LVEF, as determined
by MUGA, had to be greater than 50%. An LVEF was determined dur-
ing screening, within 14 days of the beginning of study treatment. There-
after, it was determined on weeks 8 and 16 and when clinically indicated
or when the patient had reached a withdrawal criterion.
Treatment Regimen
PLD is a doxorubicin HCl encapsulated in stealth liposomes. All
patients started treatment with a regimen of PLD in a fixed schedule
of 50 mg/m2 intravenously once every 4 weeks. Prophylactic premedi-
cation with 10mg of dexamethasone, 50mg of ranitidine, and 2mg of
tavegil was administered. In addition, supportive treatment with stan-
dard antiemetic therapy was provided. The PLD dose was reduced by
25% in patients with hematologic or skin toxicity (grade 3 or 4) or
mucositis. A phase 1 cohort consisted of a minimum of three and a
maximum of six evaluable patients. Atrasentan was administered from
day 1 in a dose-escalation manner. The starting dose was 2.5 mg and
escalated to 5 mg and later to a maximum of 10mg when noDLTwere
observed. On the basis of the single-agent phase 1 study of atrasentan,
a dose of 10 mg was chosen as the dose for further development. No
escalations beyond this dose were included in the protocol.
Atrasentan was supplied as capsules for oral use by Abbott Labora-
tories (Chicago, IL) and was taken once daily on all days of the week.
The patients entered in the phase 1 period at the maximum tolerable
dose level were included in the analysis of the phase 2 end points.
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Statistics
Duration of response was measured from the time of initial docu-
mented response to the first sign of disease progression. TTP was
measured from the date of inclusion until the time progressive disease
was documented.
The Gehan two-stage design was applied to the total study cohort,
to reject a treatment which has no success observed in the first group
of n = 14 patients (with α = 0.05 and β error < 01.0), with a prede-
termined level of activity of 20%. The number of patients in the sec-
ond stage depends on the number of responders observed during the
first stage [17].
TTP and OS analyses were performed using the Kaplan-Meier
method. For all statistical analyses, SPSS (version 15.0; IBM, Armonk,
NY) was used with a defined significance level of P < .005.
Results
The phase 1 and 2 studies were performed as a single-center study.
Patients were included between April 2003 and march 2007. Mean
age of the patients was 59 years (range = 43-74 years). More than half
of the patients had received more than one period of platinum therapy
before they became platinum-resistant. Only seven patients received
only one period of platinum therapy because of recurrent disease within
6 months after the first treatment. All patients had received taxanes as
part of their primary treatment. Patient demographics and disease
characteristics are presented in Table 1.
Phase 1
Ten patients were included in the phase 1 period of the study. The
combination of PLD and atrasentan was well tolerated at all three
atrasentan dose levels. In the first cohort, an additional patient was
included because one patient withdrew informed consent a few days
after the first administration of PLD. No dose-limiting toxicities were
assessed during the phase 1 period of the study, and atrasentan 10 mg
was selected as the dose for the phase 2 period.
Toxicity in Phase 1. All 10 patients were evaluable for the safety
analysis. Hematologic toxicity did not exceed grade 2, but grades 1 and
2 anemia were observed in almost all patients. In one patient, the dose
of PLD was reduced because of grade 4 mucositis. Other nonhemato-
logic toxicity included grade 3 to 4 nausea and vomiting observed in
20% of patients in the phase 1 period. No deaths due to toxicity oc-
curred. The complete data on toxicity are presented in Table 2.
Clinical response in Phase 1. Patients in the 2.5- and 5-mg cohorts
did not show any objective responses; however, stable disease was ob-
served in two patients for a period of 3.7 and 5.5 months, respectively.
Phase 2
Twenty-two patients were included in the phase 2 analysis of the
study, including the three patients from the 10-mg cohort of the
phase 1 period. Two patients did not meet the entry criteria (screenings
failures). Both patients had slightly decreased EF assessments at the
start of treatment. A third patient withdrew consent at day 5 of treat-
ment and was lost to follow-up. Nineteen patients were evaluable for
assessment of response. Three patients were only evaluable for toxicity
because they did not complete two courses of combination therapy;
one patient stopped after the first course because of early progression.
Two patients stopped treatment with atrasentan 10 mg during the first
course because of toxicity.
Toxicity in Phase 2. All 19 patients were evaluable for the safety
analysis. As in the phase 1 part, hematologic toxicity did not exceed
grade 2, but grades 1 and 2 anemia were observed in almost all patients.
Other nonhematologic toxicity included grade 3 to 4 nausea and
vomiting observed in 18% of the patients.
Headache, a known adverse effect of atrasentan, was observed in one
patient, and this did not diminish after reducing the dose of atrasentan
to 5 mg. After stopping atrasentan the headache resolved completely,
and this patient continued on PLD monotherapy. In another patient,
the dose of atrasentan was reduced to 5 mg because of congestive
rhinitis, and the patient was able to continue with combination treat-
ment. One patient stopped atrasentan after 2 weeks because of increas-
ing ascites and peripheral edema. This patient was found to have
progressive metastatic disease. During the phase 2 period of the study,
6 of 19 patients had a 25% dose reduction of PLD, 2 because of mu-
cositis, and 4 because of handfoot syndrome (palmar-plantar erythrody-
sesthesia [PPE]). In two patients, combination therapy was stopped per
protocol due to decreased EF. In the first patient, a grade 2 decrease in
EF was observed after two courses of therapy, and tumor evaluation
showed progressive disease. In the second patient, the EF decreased from
57% at the start of the study to 49% after four courses of therapy, and
she had stable disease on evaluation. Neither of the two patients had
clinical signs of congestive heart failure. A third patient with dyspnea
and a grade 1 decrease in LVEF was diagnosed with pericardial effusion
as the first sign of progressive metastatic disease. No deaths due to toxi-
city occurred. The complete data on toxicity are presented in Table 3.
Clinical response in Phase 2. In the 19 patients who received atra-
sentan 10 mg, a complete response was demonstrated in 1 patient and
a partial response was seen in 2 patients. An additional six patients
showed stable disease. This corresponds to an overall response rate
of 16% and demonstrable clinical benefit in 9 (46%) of 19 patients.
The three patients with objective response were all heavily pretreated
with more than one line of platinum therapy.
CA-125 response in Phase 2. All 19 patients included in the
phase 2 study population were evaluable for CA-125 response. Four
Table 1. Patients’ Characteristics.
Phase 1 Phase 2*
No. patients enrolled 10 19
Age, mean (range), years 64 (46-74) 60 (43-74)
Previous chemotherapy lines, n (%)
1 3 (30) 7 (37)
2 5 (50) 9 (47)
3 2 (20) 2 (11)
4 — 1 (5)
Dose (mg)
2.5 4
5 3
10 3 19
Initial FIGO stage
III 9 13
IV 1 6
World Health Organization performance, n (%)
0 2 (20) 6 (32)
1 5 (50) 11 (58)
Missing 3 (30) 2 (10)
LVEF, mean (range), % 65 (52-74) 64 (57-75)
FIGO indicates International Federation of Gynecology and Obstetrics.
*Including three patients on a 10-mg dose in phase 1.
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patients (21%) had confirmed CA-125 responses, including the three
patients with an objective response and one patient with stable disease.
TTP and overall survival in Phase 2. The maximum duration
of follow-up was 64 months after the start of study treatment with a
median follow-up of 13 months. A median TTP of 14 weeks (range =
0.7-45 weeks) was observed with amedianOS of 13.1months (range =
3.0-63+ months). At the time of the analysis, one patient was still alive
(OS = 63 months; Figure W1).
Discussion
Although most patients had previously received multiple lines of
platinum-containing chemotherapy, the regimen of PLD and atrasentan
was generally well tolerated. Hematologic toxicity was easily managed,
and no febrile neutropenia was observed. Dose reduction of PLD was
necessary because of handfoot syndrome (PPE) and mucositis. Hand-
foot syndrome (PPE) of any grade was not observed in the phase 1 part
of the study and in 32% of the patients in the phase 2 part, resulting in a
total incidence of 23% (6/26 patients), without any grade 3 or 4 events.
This incidence in PPE is comparable to other studies with PLD where
total incidences of up to 40% are reported with grade 3 and 4 events
ranging from 12% to 23% [9,11–13].
Cardiac assessments by MUGA scan were done repeatedly (every
two cycles), and this intensive monitoring showed a grade 1 and 2 de-
crease in cardiac EFs in two patients, without any clinical symptoms of
heart failure. Rhinitis and headache, well-recognized adverse effects of
ETreceptor antagonists, were observed in 42% and 37%, respectively,
of the patients receiving a daily dose of atrasentan 10mg. Safety studies
performed with atrasentan 10 mg demonstrated incidences between
0% and 100% for headaches and between 0% and 67% for rhinitis.
Across all doses of atrasentan, headaches were experienced by more
than 60% of patients, and rhinitis was reported for 50% to 100%
of the patients. The incidence of headaches and rhinitis was dose-
dependent, with the highest incidence seen in the higher-dose cohorts
(>60 mg). In the current study, one patient discontinued because of
headaches even after lowering the atrasentan dose to 5 mg.
Overall, the addition of atrasentan did not seem to increase the tox-
icity of PLD. PLD is a well-known, non–cross-resistant drug available
for patients with platinum-paclitaxel–resistant ovarian cancer. Gordon
et al. [18] showed in a phase 2 study of monotherapy PLD a response
rate of 18.3% for platinum- and paclitaxel-refractory patients. In
a phase 3 study in 474 patients, in which PLD was compared with
topotecan, the response rate for PLD was 12.3% [19]. The response
rate observed in this study was 16% and therefore similar to that ob-
served in previous studies with PLD. In the aforementioned phase 3
study, the median TTP was 9.1 weeks, with a median OS of 35 weeks.
In our study, median TTP was 14 weeks and median OSwas 57 weeks
(13.1 months). Although one cannot compare phase 2 and 3 data,
there is some suggestion of increased survival in our patient popula-
tion, possibly due to the addition of atrasentan.
Several other non–cross-resistant agents have demonstrated activity
after failure of platinum-paclitaxel regimens, although in some studies,
platinum-sensitive and platinum-resistant patients were combined. In
phase 2 studies of monotherapy of gemcitabine in patients with ad-
vanced ovarian cancer after platinum and paclitaxel, response rates
of 13% and 13.9% were observed [20]. In the study of Shapiro
et al. [21], 29% of the patients were still considered to be potentially
platinum-sensitive, and no data on TTP or OS were given. In the
study by Friedlander et al. [22] 16 of 38 patients were still platinum-
sensitive. In this study, an OS of 6.7 months was observed. Rose
et al. [23] studied prolonged oral etoposide in platinum-resistant
Table 3. Response and Response Duration.
Response
RECIST response (n = 19), n (%)
CR 1 (5)
PR 2 (11)
SD 6 (32)
PD 10 (52)
CA-125 response (n = 19), n (%)
Response 4 (21%)
No response 15 (79%)
TTP (n = 22), weeks
Median (range) 14 (0.7-45)
Overall survival (n = 22), months
Median (range) 13.1 (3-63+)
PD indicates progressive disease; SD, stable disease.
Table 2. Adverse Events.
Adverse Event Phase 1 (n = 10) Phase 2 (n = 19)*
All grades (n) All grades (%) Grade 3/4 (n) Grade 3/4 (%) All grades (n) All grades (%) Grade 3/4 (n) Grade 3/4 (%)
Hematologic
Anemia 7 70 1 10 15 88 0
Leukopenia 4 40 1 10 6 35 0
Thrombocytopenia 2 20 0 5 29 0
Nonhematologic
Nausea and vomiting 8 80 2 20 18 95 3 16
Mucositis 6 60 1 10 12 63 1 5
Anorexia 3 30 0 7 41 0
Headache 1 10 0 7 41 1 6
Peripheral edema 3 30 0 7 41 0
Rhinitis 1 10 0 8 47 0
PPE 0 0 6 35 0
Metabolic
Hyponatremia 7 70 1 10 5 29 1 6
Hypokalemia 4 40 1 10 16 94 0
Hypoalbuminemia 6 60 1 10 7 41 0
Creatinine 2 20 0 1 6 0
*Including three patients on a 10-mg dose in phase 1.
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and platinum-sensitive ovarian cancer and observed in the platinum-
resistant group a response rate of 26.8% with a PFS of 5.7 months and
an OS of 10.8 months. Topotecan is another currently used drug in
advanced ovarian cancer. In a phase 2 study by Bookman et al. [24],
a group of 139 patients of whom81%were platinum-resistant received
intravenous topotecan as second-line treatment. In the group with
platinum-resistant disease, a response rate of 12.4%was observed, with
a TTP of 11 weeks and an OS of 45 weeks.
In conclusion, the addition of atrasentan to PLD can be done safely
in platinum-pretreated patients with resistant ovarian cancer. The com-
bination has an antitumor activity similar to that reported for other
chemotherapeutics in this patient population, although the TTP was
relatively long. Further studies with endothelin receptor antagonists in
platinum-refractory ovarian cancer patients are therefore warranted.
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